

sulphur or an oxygen

Y_2 represents a -NH group or nitrogen;

Z represents oxygen, sulphur, -N-CN or -CH-NO₂; and

R_1 and R_2 , which can be identical or different, represent each independently a linear or ramified alkyl group, saturated or unsaturated with 2 to 12 carbon atoms, an alicyclic group, saturated or unsaturated with 3 to 12 carbon atoms, eventually radioactive, an aryl group, substituted or not by one or several alkyl groups in C₁-C₄, nitro, cyano, trifluoromethyl, carboxy and halogen groups, or an arylalkyl group,

or R_1 and/or R_2 form with Y_1 and/or Y_2 a 5 to 7 membered heterocyclic group, saturated or unsaturated

with the exception of derivatives for which X is a nitro group, Y_1 represents a secondary amine group (-NH-), Y_2 represents a -NH group, Z an oxygen, R_2 , an isopropyl and R_1 an element selected in a group constituted of (m-toluhl, phenyl and cyclooctyl) and with the exception of N-[(2-cyclooctylamino-5-cyanobenzene)sulfonyl] N'-isopropyl urea.

13. Derivate according to claim 12, characterized in that X represents nitro, cyano, bromo, iodine group.

14. Derivate according claim 12, characterized in that Y_1 represents a -NH group and Y_2 represents a -NH group or an oxygen atom.

15. Derivate according to claim 12, characterized in that R_1 and R_2 represent each independently an ethyl, butyl, tert-butyl, propyl, isopropyl, pentyl, hexyl, heptyl, octyl, decyl,

amyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, 2-cyclohexenyl, m-toluy, o-toluy, p-toluy, phenyl, allyl, adamantyl, norbornyl; caproyl, 3-carboxyphenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,4,6-trimethylphenyl, furfuryl, benzyl or 1-phenylthyl group.

16. Derivate according to claim 12, characterized in that R_2 and Y_2 form a homopiperidin group.

17. Derivate according to claim 12, characterized in that R_1 and Y_1 form a morpholin or homopiperidin group.

18. Derivate according to claim 12, characterized in that it is constituted by a salt chosen into the group formed by sodium salts, the potassic salts and the amino acid salts such as lysine, arginine.

19. Derivate according to claim 18, characterized in that it is chosen in a group having:
N-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]N'-tert-butyl urea,
N-cyano-N'-[(2-metatoluylamino-5-nitrobenzene)sulfonyl]homopiperidinoamidine,
N-[(2-cycloheptylamino-5-nitrobenzene)sulfonyl]N'-cyclohexyl thiourea, and
N-[(cyclohexen-2-yl)-5-iodobenzene)sulfonyl]N'-pentyl urea.

20. Pharmaceutical composition, characterized in that it includes a benzene sulphonamide derivate according to claim 12 in mixture with an acceptable pharmaceutical excipient and eventually other therapeutic agents.

21. Use of a derivate according to claim 12, for the production of a medicament for the treatment and/or the prevention of the illnesses involving the thromboxan A2, such as for cardiovascular and blood, pulmonary, reproduction and renal use.

22. Use of a radiolabelled derivate according to claim 12, as binding to thromboxan A2 receptor.


REMARKS

Claims 12-22 replace claims 1-11, in order to delete multiple dependencies.

Favorable action is requested.

Respectfully submitted,

By:



William E. Player

Reg. No. 31,409

JACOBSON HOLMAN PLLC
400 Seventh Street, N.W.
The Jenifer Building
Washington, D.C. 20004
Tel.: (202) 638-6666
Atty. Dkt. No.: P66806US0

G:\CFINK\NEWAPPLS\NEWAPPLN\PCT\P66806US0prel.wpd